Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 14/20 | 0.73 |
| ▸ | PPARG | P37231 | 12/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | PPARD | Q03181 | 7/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | FABP2 | P12104 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4575444 | 0.90 | PPARA (0.75) | PPARAPPARGMEN1CYP1A2CYP3A4 | |
| SCHEMBL5794669 | 0.86 | PPARG (0.72) | PPARAPPARGMEN1CYP1A2CYP3A4 | |
| SCHEMBL3845467 | 0.85 | PPARA (1.00) | PPARAPPARGMEN1CYP1A2CYP3A4 | |
| SCHEMBL4575624 | 0.84 | PPARA (0.53) | PPARAPPARGCYP1A2CYP3A4MAPT | |
| SCHEMBL4042833 | 0.83 | PPARA (0.73) | PPARAPPARGMEN1CYP1A2CYP3A4 | |
| SCHEMBL4575316 | 0.83 | PPARA (0.51) | PPARAPPARGCYP1A2CYP3A4PPARD | |
| SCHEMBL2558984 | 0.82 | PPARA (0.71) | PPARAPPARGMEN1CYP1A2CYP3A4 | |
| SCHEMBL3839840 | 0.82 | PPARA (1.00) | PPARAPPARGMEN1CYP1A2CYP3A4 | |
| SCHEMBL3848011 | 0.81 | PPARA (0.69) | PPARAPPARGPPARD | |
| SCHEMBL1550078 | 0.81 | PPARA (0.64) | PPARAPPARGCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2000751-A | — | — | None | — | — | JP | disclosed |
| EP-1661890-B1 | PPAR-ACTIVATING COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | KOWA CO (JP) | 2011-01-05 | — | — | EP | disclosed |
| EP-1856065-B1 | 1,2,4-TRIAZINE DERIVATIVES, PREPARATION AND USE THEREOF IN HUMAN THERAPY | PF MEDICAMENT (FR) | 2009-11-11 | — | — | EP | disclosed |
| US-7319104-B2 | hPPARs activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| WO-2007118964-A1 | SUBSTITUTED N-(PHENETHYL)BENZAMIDE DERIVATIVES, PREPARATION AND USES THEREOF | GENFIT (FR) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007118963-A2 | SUBSTITUTED N-(PHENETHYL)BENZAMIDE DERIVATIVES, PREPARATION AND USES THEREOF | GENFIT (FR) | 2007-10-25 | — | — | WO | disclosed |
| US-7183295-B2 | PPAR-activating compound and pharmaceutical composition comprising the compound | KOWA CO., LTD. (JP) | 2007-02-27 | — | — | US | disclosed |
| US-7109226-B2 | PPAR-activating compound and pharmaceutical composition comprising the compound | KOWA CO., LTD. (JP) | 2006-09-19 | — | — | US | disclosed |
| US-20060189667-A1 | PPAR-activating compound and pharmaceutical composition comprising the compound | KOWA CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| EP-1661890-A1 | PPAR-ACTIVATING COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Kowa Co., Ltd. (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-5872282-A | MAINTAIN OXYGEN AFFINITY IN BLOOD WHEN STORED | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1999-02-16 | — | — | US | disclosed |
| US-5731454-A | Allosteric modifiers of hemoglobin useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1998-03-24 | — | — | US | disclosed |
| US-5705521-A | Use of allosteric hemoglobin modifiers in combination with radiation therapy to treat carcinogenic tumors | THE CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1998-01-06 | — | — | US | disclosed |
| US-5677330-A | THERAPY HYPOXIA, HYPOTHERMIA, ISCHEMIC, WOUNDS, ULCERS, TISSUE TRANSPLANTS, SESPIS | THE CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1997-10-14 | — | — | US | disclosed |
| US-5591892-A | CARBOXYALKOXYPHENYL SUBSTITUTED INDANES | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1997-01-07 | — | — | US | disclosed |
| JP-H02751-A | PREPARATION OF 2-(4-(2-(4-CHLOROBENZAMIDE)ETHYL) PHENOXY)-2-METHYL PROPIONIC ACID | KRKA TOVARNA ZDRAVIL | 1990-01-05 | — | — | JP | disclosed |
| EP-0004011-B1 | PHENOXYALKYLCARBOXYLIC-ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | Roche Diagnostics GmbH (DE) | 1981-04-01 | — | — | EP | disclosed |
| US-4258058-A | Phenoxyalkylcarboxylic acid compounds and thrombocyte-aggregation inhibition | BOEHRINGER MANNHEIM GMBH (DE) | 1981-03-24 | — | — | US | disclosed |
| US-4153728-A | ANTICHOLESTEROL AGENTS, ANTILIPEMIC AGENTS, ANTICOAGULANTS | BOEHRINGER MANNHEIM GMBH (DE) | 1979-05-08 | — | — | US | disclosed |
| US-4151303-A | Phenoxyalkylcarboxylic acid compounds and serum-lipid and triglyceride depressing therapeutic compositions | BOEHRINGER MANNHEIM GMBH (DE) | 1979-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189667-A1 | PPAR-activating compound and pharmaceutical composition comprising the compound | PPARA, PPARG, PPARD | PPARA 1/4885PPARG 2/4885MEN1 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.